Tukysa
Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu
Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance